¹ Optimal Pre-dilatation Treatment before Implantation of a ² Magmaris Bioresorbable Scaffold in Coronary Artery ³ Stenosis. The OPTIMIS trial

4

- 5
- 6 Kirstine Nørregaard Hansen MD^{1,2}, Jens Trøan MD¹, Akiko Maehara MD³, Manijeh Noori MD^{1,2},
- 7 Mikkel Hougaard MD PhD¹, Julia Ellert-Gregersen MD PhD¹, Karsten Tange Veien MD¹, Anders
- 8 Junker MD PhD¹, Henrik Steen Hansen MD^{1,2}, Jens Flensted Lassen MD PhD^{1,2}, Lisette Okkels
- 9 Jensen MD DMSci $PhD^{1,2}$
- 10
- 11
- 12 ¹Department of Cardiology, Odense University Hospital, Odense, Denmark
- 13 ²University of Southern Denmark, Odense, Denmark
- ³Cardiovascular Research Foundation, New York Presbyterian Hospital, New York, USA

15

- 16 Short title: Bioresorbable scaffolds and lesion preparation
- 17 Word count: 4,805

18

Correspondence to: Kirstine Nørregaard Hansen MD Odense University Hospital Department of Cardiology Sdr. Boulevard 29 5000 Odense C Denmark E-mail: kirstinenoerregaard@live.dk Phone: +45 6541 2690

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Version 4.6 18.6.24

20 **Abstract**

 Introduction: Bioresorbable scaffolds (BRS) have been developed to overcome limitations related to late stent failures of drug-eluting-stents, but previous studies have observed lumen reduction over time after implantation of BRS. The aim of the study was to investigate if lesion preparation with a scoring balloon compared to a standard non-compliant balloon minimizes lumen reduction after implantation of a Magmaris BRS (MgBRS) assessed with optical coherence tomography (OCT) and intravascular ultrasound (IVUS).

 Method: Eighty-two patients with stable angina pectoris were included and randomized in a ratio 1:1 to lesion preparation with either a scoring balloon or a standard non-compliant balloon prior to implantation of a MgBRS. The primary endpoint was minimal lumen area (MLA) 6 months after MgBRS implantation.

Results: Following MgBRS implantation, MLA $(6.4 \pm 1.6 \text{ mm}^2 \text{ vs. } 6.3 \pm 1.5 \text{ mm}^2, \text{ p=0.65})$, mean 32 scaffold area $(7.8 \pm 1.5 \text{ mm}^2 \text{ vs. } 7.5 \pm 1.7 \text{ mm}^2, \text{ p=0.37})$, and mean lumen area $(8.0 \pm 1.6 \text{ mm}^2 \text{ vs. } 1.5 \text{ mm}^2, \text{ s=0.37})$ 33 7.7 ± 2.1 mm², p=0.41) did not differ significantly in patients where the lesions were prepared with 34 scoring vs. standard non-compliant balloon respectively. Six-month angiographic follow-up with 35 OCT and IVUS was available in seventy-four patients. The primary endpoint, 6-months MLA, was 36 significantly larger in lesions prepared with a scoring balloon compared to a standard non-37 compliant balloon $(4.7 \pm 1.4 \text{ mm}^2 \text{ vs. } 3.9 \pm 1.9 \text{ mm}^2, \text{ p=0.04})$, whereas mean lumen area $(7.2 \pm 1.4 \text{ mm}^2, \text{ s=0.04})$ 38 mm³ vs. 6.8 ± 2.2 , p=0.35) did not differ significantly. IVUS findings showed no difference in 39 mean vessel area at the lesion site from baseline to follow-up in the scoring balloon group (16.8 \pm 40 2.9 mm² vs. 17.0 \pm 3.6 mm², p=0.62), whereas mean vessel area (17.1 \pm 4.4 mm² vs. 15.7 \pm 4.9 41 mm², p<0.001) was smaller in lesions prepared with a standard non-compliant balloon due to 42 negative remodeling.

Version 4.6 18.6.24

- 43 **Conclusion**: Lesion preparation with a scoring balloon prior to implantation of a MgBRS resulted
- 44 in significantly larger MLA after 6 months due to less negative remodeling compared to lesion
- 45 preparation with a standard non-compliant balloon.
- 46 Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04666584.

Version 4.6 18.6.24

Clinical perspectives:

What is new?

- Intense lesion preparation with a scoring balloon prior to implantation of a magnesium-

Version 4.6 18.6.24

63 **Introduction**

64 Bioresorbable scaffolds (BRS) were developed to provide temporary vessel support during the early 65 phases of coronary vessel healing, leaving the artery stent-free after degradation as an alternative to 66 drug-eluting stents (DES) during percutaneous coronary intervention (PCI)^{1, 2}. The potential 67 advantages of BRS were restored vasomotion and potential reduction in late stent failures. The 68 Absorb everolimus-eluting BRS (Abbott Vascular, Abbott Park, IL, USA) showed increased risk of 69 scaffold thrombosis and vessel shrinkage over time³ with significant minimal lumen area (MLA) 70 reduction after 6 months assessed with optical coherence tomography $(OCT)^4$. It is hypothesized 71 that the mechanism behind lumen reduction is based on decreased radial strength in BRS compared 72 with bare-metal stents and risk of recoil and scaffold dismantling⁵. The construction of BRS 73 continued to develop, and different types are now available on the market. The magnesium-based 74 BRS (Magmaris, Biotronik, Bülach, Switzerland) (MgBRS) was later introduced with improved 75 radial strength, stronger backbone, change in drug-polymer coating and showed better efficacy 76 compared to the first $BRSs^{6-9}$. Head-to-head comparison between newer generation DES and the MgBRS is limited, but the anti-restenotic efficacy has not yet solved the scaffold failure^{5, 10}. 78 Optimal lesion preparation prior to implantation of a MgBRS appeared to facilitate optimal scaffold γ sizing and better expansion post-procedure in complex lesions¹¹, but the effect of aggressive pre-80 dilation on vessel and lumen changes over time is uncertain. Peri-procedural intravascular imaging 81 is recommended during implantation of a MgBRS due to lack of a radiolucent backbone. OCT is 82 ideal to assess lumen contours¹², whereas intravascular ultrasound (IVUS) provides information on 83 the vessel wall and vessel remodeling over time^{13, 14}. The aim of this study was to assess whether a 84 more aggressive lesion preparation with a scoring balloon compared to a standard non-compliant 85 balloon prior to implantation of a MgBRS resulted in less lumen reduction MLA after 6 months.

86

87 **Methods**

Version 4.6 18.6.24

Study design

Patient population

 Eighty-two patients with stable angina pectoris referred to PCI were enrolled in the study, if they met the inclusion criteria. Patients were eligible if; 1) age was between 18 and 80 years, 2) if they had stable angina pectoris, 3) the target lesion was in a native coronary artery, 4) vessel was suitable for treatment with MgBRS complying with the scaffolds recommended limitations of coronary 108 artery diameter between \geq 2.75 mm and \leq 4.0 mm measured with OCT or IVUS. Exclusion criteria were 1) patients participating in other randomized stent studies, 2) expected survival < 1 year, 3) allergy to aspirin, ticagrelor, clopidogrel or prasugrel, 4) allergy to sirolimus, 4) ostial lesions (cannot be cleared with flush by OCT), 5) serum creatinine > 150 µg/L (due to the required amount

Version 4.6 18.6.24

Version 4.6 18.6.24

Procedure strategy

 The coronary stenosis was identified by the PCI operator's interpretation of the angiography and was treated with a MgBRS in all patients. Patients received a dose of heparin (70 UI/kg) prior to the procedure. At the discretion of the operator, pre-dilatation with a 2.0 mm balloon was allowed. Pre- interventional imaging with OCT and IVUS was performed. The scaffold sizing was based on the external elastic membrane (EEM) diameters of the proximal and distal reference segments. If the EEM was visible in >180º of the cross sectional area, the smaller EEM diameter rounded down to 144 the nearest 0.5 mm was used to determine scaffold diameter. If the EEM was visible in <180°, the scaffold diameter was based on the lumen diameter¹⁷. Patients were allocated 1:1 to either lesion preparation with 1) a scoring balloon, or 2) a standard non-compliant balloon. The lesion was pre- dilated in a 1:1 balloon:artery ratio. Up-scaling to a 0.5 mm larger balloon was allowed, if the pre- dilatation goal was not achieved, as long as the balloon type corresponded to the randomization arm. The pre-dilatation goal was an angiographic residual stenosis of less than 20%. The lesion was then treated with implantation of a MgBRS, and inflation pressure was maintained for 30 seconds during implantation. Mandatory post-dilatation was performed with a non-compliant balloon with the same size or maximally 0.5 mm larger than the implanted scaffold. Lastly, intravascular imaging with OCT and IVUS of the scaffold treated segment was performed and controlled by the PCI-operator and an on-site OCT-analyst. Optimization (if any) was performed at the operators' discretion. Additional intervention was allowed if there was 1) major under-expansion (minimal 156 scaffold area (MSA) < 4.5 mm²), 2) major malapposition (defined as strut > 0.3 mm from the lumen wall for > 3 mm), 3) presence of significant edge dissection, or 4) residual stenosis <5 mm proximal 158 or distal to the scaffold (causing MLA $<$ 4 mm²). Repeated OCT and IVUS of the final result were

Version 4.6 18.6.24

- then performed. Blinding of the patient, PCI-operator or investigator to pre-dilatation technique was not possible during the index procedure.
-

Intravascular imaging acquisition

- OCT and IVUS were performed at baseline and after 6-month of follow-up. The imaging
- procedures were preceded by administration of 200 µg of intracoronary nitroglycerin. OCT was
- performed with frequency-domain OPTIS OCT system (Illumien OCT system; Abbott Vascular,
- 166 Santa Clara, CA, USA) using the DragonflyTM Imaging catheter. The catheter was positioned 10
- mm distally to the lesion or scaffold-treated segment, and the coronary artery was then flushed with
- 15 ml contrast injection to clear the artery for blood during automated pullback at a rate of 20 mm/s
- over a distance of 75 mm. The IVUS system (Boston Scientific, Marlborough, MA, USA) used a
- 40MHz OptiCross 2.6 Fr catheter placed 10 mm distally to the lesion or scaffold-treated segment.
- Motorized IVUS pullbacks were performed with a pullback speed of 0.5 mm/sec after intracoronary
- 172 bolus of 200 µg nitroglycerine.
-

Intravascular imaging analysis

 The intravascular imaging pullbacks were analyzed by two independent analysists who were both blinded to the pre-dilatation technique during analysis. The baseline IVUS and OCT pullbacks were matched with the follow-up images using anatomical landmarks. OCT offline software (Offline Review Workstation; Abbott Vascular) was used for quantitative OCT analysis, and the commercially available program for computerized IVUS-analysis Echoplaque (INDEC Systems, Inc., Santa Clara, CA, USA) was used for IVUS-analysis. The scaffold-treated segment was analyzed for every mm. Lumen dimensions at baseline and follow-up were measured: MLA, mean lumen area, lumen volume, and difference in MLA (follow-up MLA – baseline MLA). Quantitative

Version 4.6 18.6.24

Statistical analysis

Version 4.6 18.6.24

- strength of the linear relation between two parameters.
- 217 The estimated sample size was based on data from the HONEST study¹⁹. The reduction of MLA

218 from 6.99 mm² to 5.01 mm² (27%) 6 months after implantation of the Magmaris BVS, represented the expected reference group. Optimal lesion preparation with pre-dilatation with a scoring balloon 220 is estimated to minimize MLA reduction from 6.99 mm² to 6.22 mm² (11%). A power calculation is conducted using the expected MLA after 6 months (6.22 mm² for the scoring balloon and 5.01 mm² for the standard non-compliant balloon). Inclusion of 35 patients in each group is necessary to reach statistical significance in case of 2-tailed significance level of 0.05 and power of 80 %. Loss to follow-up and poor image quality finalize an expected drop-out rate of 15 %, thereby requiring 82

patients in total.

Endpoints

 The primary endpoint was MLA in the scaffold-treated segment pre-dilated with a scoring balloon versus standard non-compliant balloon 6-month after implantation of a MgBRS assessed with OCT.

Version 4.6 18.6.24

-
- **Results**

A flowchart of enrolled patients is provided in Figure 1.

 In total, 82 patients were enrolled in the study. Follow-up images were not available in 8 patients due to following reasons. One patient randomized to standard non-compliant balloon pre-dilatation was excluded due to vessel dissection that could not be covered by a MgBRS scaffold. Two patients were excluded, one in the scoring balloon group and one in the standard non-compliant balloon group, due to scaffold failure where the MgBRS was lost in the coronary artery proximally to the study lesion. In all three cases, patients were treated with a DES. Five patients had unavailable follow-up images: Two patients withdrew consents (one in the scoring balloon group and one standard non-compliant balloon group), one patient died within the 6-month angiographic follow-up (standard non-compliant balloon group), one patient had a subacute scaffold thrombosis 5 days after implantation (standard non-compliant balloon group), and one patient was postponed due to nurses' strike (standard non-compliant balloon group).

Clinical and procedural characteristics

Baseline clinical and procedural characteristics are presented in Table 1 and Table 2.

The treatment groups were well matched without any significant differences in baseline

characteristics. Also, there were no significant differences in procedural characteristics, except for

251 balloon length which was significantly shorter in the scoring balloon group (only available in 10

252 and 15 mm) (13.1 \pm 2.5 mm vs. 15.5 \pm 3.3 mm, p < 0.001) compared to the standard non-compliant balloon group.

Version 4.6 18.6.24

254

255 *Optical coherence tomography findings*

- 256 Post-procedure and 6-month follow-up OCT findings are presented in Table 3. Inter-observer
- 257 variability for MLA at follow-up was: ICC=0.996 (95% confidence interval (CI): 0.999-1.00,
- 258 p<0.001), for total malapposition area at baseline: ICC=0.949 (95% CI: 0.77-0.99, p< 0.001), and
- 259 for total malapposition at follow-up: ICC=0.874 (95% CI: 0.50-0.97, p=0.001).

260

261 Lumen dimensions

 At baseline, there was no significant difference in MLA, mean LA, or lumen volume between the two treatment groups assessed with OCT. At 6-month follow-up, MLA (the primary endpoint) in the scaffold-treated segment was significantly larger in the patients allocated to pre-dilatation with a 265 scoring balloon, compared to a standard non-compliant balloon (4.71 mm² \pm 1.35 vs. 3.91 mm² \pm 266 1.86, $p = 0.04$). There was no significant difference between the two groups in mean LA, or lumen volume at 6-month follow-up. There was a relative reduction in MLA of -24.8% for the scoring 268 balloon group compared to -38.3% in the standard non-compliant balloon group, p=0.009. Representative cases of lumen reduction from baseline to follow-up are shown in Figure 2.

270

271 Scaffold measurements and malapposition

272 At baseline, scaffold parameters, such as scaffold length, mean scaffold area, minimal scaffold area, 273 and total scaffold volume were similar in the two groups. Total number of analyzable struts were 274 similar at baseline between the two groups (199.9 \pm 70.5 in the scoring balloon group and 210.7 \pm 275 60.0 in the standard non-compliant balloon group, p=0.46). At follow-up, the total number of 276 analyzable struts were reduced to 70.8 ± 35.1 in the scoring balloon group and 85.1 ± 32.1 in the 277 standard non-compliant balloon group $(p=0.07)$.

Version 4.6 18.6.24

Version 4.6 18.6.24

 Post-procedure and 6-month follow-up IVUS findings are presented in Table 3 and Table 4 and Supplementary table 1.

Vessel dimensions

 There was no difference in vessel measurements between the two groups at baseline or at 6-month follow-up (Table 3). The paired analysis of mean area in the 10 mm lesion site and corresponding segment post-procedure and at 6-month follow-up are presented in Table 4. There was no significant difference in mean lumen area from post-procedure to 6-month follow-up in the scoring 309 balloon group $(8.5 \pm 1.4 \text{ mm}^2 \text{ vs. } 8.1 \pm 1.8 \text{ mm}^2, \text{ p=0.08})$, whereas a significant decrease in lumen 310 area was found in the standard non-compliant balloon group (8.2 \pm 1.7 mm² vs. 7.4 \pm 2.6 mm², p=0.009). Vessel area in the 10 mm segment corresponding to the lesion site did not change in the 312 scoring balloon group from baseline to 6-month follow-up (16.8 ± 2.9 mm² vs. 17.0 ± 3.6 mm², $p=0.62$), but was significantly decreased (17.1 \pm 4.4 mm² vs. 15.7 \pm 4.9 mm², p < 0.001) in the

standard non-compliant balloon group indicating negative remodeling.

Pattern of remodeling

 Figure 4 shows the relationship between relative change in lumen area and relative change in vessel area (A), and relative change in lumen area and relative change in plaque area (B). There was a significant positive correlation between relative change in lumen area and relative change in vessel area at the 10 mm lesion site (r=0.72, 95% CI: 0.58-0.81, p<0.001), but there was no correlation between relative change in lumen area and relative change in plaque area (r=-0.02, 95% CI: -0.25- 0.21 , p=0.88).

Version 4.6 18.6.24

Clinical 6-month follow-up

 In patients allocated to pre-dilatation with a scoring balloon prior to implantation of the MgBRS one patient had a target vessel revascularization not related to the scaffold-treated segment. There were no events observed corresponding to the scaffold-treated segment in the scoring balloon group. In patients treated with the standard balloon prior to implantation of the MgBRS following events were observed: one patient admitted with STEMI and subacute scaffold thrombosis 5 days after index procedure. This patient was only treated with aspirin for 4 days followed by monotherapy with clopidogrel as the patient also received NOAC; one patient died due to an intracranial hemorrhage 92 days after index procedure. **Discussion**

 In summary, we found that MLA assessed with OCT was significantly larger in the scoring balloon group compared to the standard non-compliant balloon group 6 month after implantation of the MgBRS. In both groups, MLA decreased from baseline to 6-month follow-up, but less MLA reduction was seen in the scoring balloon group compared to the standard non-compliant balloon group. At the lesion site, there was no change in remodeling from baseline to follow-up in the scoring balloon group, whereas negative remodeling was observed in lesions prepared with the standard non-compliant balloon. In the lesions pre-dilated with a scoring balloon, there was significantly less malapposition at follow-up compared to the standard non-compliant balloon group.

344 The magnesium-based BRS was first evaluated in the DREAM 1G study²⁰, where a significant 345 decrease in MLA was observed within the first 6 months (7.9 mm² \pm 1.2 vs. 5.7 mm² \pm 1.0) after implantation assessed with OCT. The second generation magnesium-based BRS, MgBRS, had 347 higher flexibility and higher radial force, than the first generation magnesium-based BRS²¹.

Version 4.6 18.6.24

Version 4.6 18.6.24

371 The HONEST trial²⁵ comparing OCT- and angio-guided implantation with the MgBRS in a population with acute coronary syndrome found a significant reduction in MLA observed after 6 month in both groups with a relative difference of 33.2 % and 22.8 % in MLA, respectively. The mechanism behind lumen reduction may be due to additional post-dilatation in an attempt to optimize the apposition, resulting in fracture or dismantling of the scaffold hence reducing the 376 radial strength²⁶. Other mechanisms contributing to premature lumen loss after implantation of the MgBRS could be scaffold recoil, neointimal hyperplasia and impact of underlying plaque 378 morphology and vessel remodeling⁵. The pattern of remodeling, with significant correlation between change in lumen area and change in vessel area, but not between change in lumen area and plaque area, indicated vessel reduction and not plaque increase as the overall reason for lumen reduction. The pattern of remodeling was similar in the two groups, but the overall magnitude of vessel reduction causing lumen reduction was larger in the standard non-compliant balloon group compared the scoring balloon group. Our results reported significantly more decrease in vessel area in lesions prepared with a standard non-compliant balloon, which was not seen in the lesions pre- dilated with the scoring balloon. This indicates that negative remodeling and vessel shrinkage may be contributing factors for lumen loss in our study in the standard non-compliant balloon group. In the ABSORB Cohort B trial, dynamics of the vessel wall was investigated with IVUS after implantation the everolimus-eluting bioresorbable ABSORB scaffold. They reported no evidence of late recoil, but enlargement of the vessel, lumen and scaffold area up to three years after 390 implantation²⁷. The early resorption of the MgBRS with fast loss of radial force has been suggested 391 as a limiting factor to the device, and must be investigated further⁵. The extent of scaffold recoil is a balance between elastic recoil and radial strength and can be affected by the fibrotic plaque in the 393 coronary artery in the treated segment⁵. Optimal pre-dilatation with a more aggressive lesion 394 preparation could result in a better vascular healing and less lumen reduction¹¹. More lipid-rich

Version 4.6 18.6.24

 plaques have been associated with less lumen loss after implantation of the MgBRS, whereas the 396 constrictive vascular forces and rigidity of fibrotic plaque may facilitate lumen reduction⁵. Patients with acute coronary syndrome tend to have lesions with more lipid-rich plaque and positive remodeling compared to our population of patients with stabile coronary syndrome, which could explain more lumen reduction than expected in the current study. Percentage of post-procedure malapposed struts was small in our study in both groups (1.46% for scoring balloon group and 4.57% for the standard non-compliant balloon group). As shown in 402 previous trials^{5, 19, 20, 22}, most struts will not be visible after 6 months, due to the fast scaffold absorption. Even though we found up to 43% of the scaffolds with malapposition had follow-up, the percentage of malapposed struts and malapposition volume was low. Significantly less malapposition was present in the scoring balloon group compared to the standard non-compliant balloon group, which contributes to the assumption of better vascular healing after lesion preparation with a scoring balloon. To determine if these findings are a part of the natural healing process needs longer follow-up time. Despite reported lumen loss after implantation of the MgBRS in various intravascular imaging 410 studies^{19, 22}, the clinical performance is still deemed safe and efficient in several studies. Registries have reported safety and efficacy with low 1-year TLF rates of 3.3-5.4% and stent thrombosis rates 412 of 0.5%, and TLF of 7.8% and scaffold thrombosis of 0.5% up to 24 months after implantation^{9, 28,} $\frac{29}{2}$. A registry study found no difference in 24-month clinical outcomes between patients with acute 414 vs. stable coronary syndromes who were treated with a $MgBRS³⁰$. Only few studies have compared the MgBRS to DES, for example the MAGSTEMI trial (MAGnesium-based bioresorbable scaffold in ST-segment Elevation Myocardial Infarction) that showed a significantly higher TLF rate in the 417 MgBRS group after 1 year in a ST-segment elevation myocardial infarction population¹⁰. However, a retrospective cohort reported similar 1-year clinical outcome comparing the MgBRS to a

Version 4.6 18.6.24

Version 4.6 18.6.24

References

- 1. Azzi N, Shatila W. Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization. *Rev Cardiovasc Med*. 2021;22:137-145
- 2. Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, et al. Arterial remodeling after bioresorbable scaffolds and metallic stents. *Journal of the American College of Cardiology*. 2017;70:60-74
- 3. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, et al. 2-year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: A systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. *Lancet (London, England)*. 2017;390:760-772
- 4. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. *Circulation*. 2010;122:2301-2312
- 5. Ueki Y, Räber L, Otsuka T, Rai H, Losdat S, Windecker S, et al. Mechanism of drug-eluting absorbable metal scaffold restenosis: A serial optical coherence tomography study. *Circulation. Cardiovascular interventions*. 2020;13:e008657
- 6. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, et al. Safety and performance of the drug- eluting absorbable metal scaffold (dreams) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man biosolve-i trial. *Lancet (London, England)*. 462 2013;381:836-844
463 7. Haude M. Ince H.
- 7. Haude M, Ince H, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (dreams 2g) in patients with de novo coronary lesions: Three-year clinical results and angiographic findings of the biosolve- ii first-in-man trial. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2020;15:e1375-e1382
- 8. Haude M, Toelg R, Lemos PA, Christiansen EH, Abizaid A, von Birgelen C, et al. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the biosolve-ii first-in-man trial at 5 years. *Cardiovascular revascularization medicine : including molecular interventions*. 2022;38:106-110
- 9. Verheye S, Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Haude M, et al. Biosolve-iv-registry: Safety and performance of the magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2021;98:E1-e8
- 10. Sabaté M, Alfonso F, Cequier A, Romaní S, Bordes P, Serra A, et al. Magnesium-based resorbable scaffold versus permanent metallic sirolimus-eluting stent in patients with st-segment elevation
- myocardial infarction: The magstemi randomized clinical trial. *Circulation*. 2019;140:1904-1916 11. Miyazaki T, Latib A, Ruparelia N, Kawamoto H, Sato K, Figini F, et al. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: A comparison with conventional balloon predilatation. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2016;11:e1580-1588
- 12. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the international working group for intravascular optical coherence tomography standardization and validation. *Journal of the American College of Cardiology*. 2012;59:1058-1072
- 13. Mintz GS, Guagliumi G. Intravascular imaging in coronary artery disease. *Lancet (London, England)*. 2017;390:793-809
- 14. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus). A report of the american college of cardiology

Version 4.6 18.6.24

Version 4.6 18.6.24

- lesions in native coronary arteries: Pooled 12-month outcomes of biosolve-ii and biosolve-iii. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2018;92:E502-e511
- 30. Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, Aprigliano G, et al. Comparison of acute versus stable coronary syndrome in patients treated with the magmaris scaffold: Two-year results from the magmaris multicenter italian registry. *Cardiovascular revascularization medicine : including molecular interventions*. 2023;57:53-59
- 31. Rola P, Włodarczak A, Włodarczak S, Barycki M, Szudrowicz M, Łanocha M, et al. Magnesium bioresorbable scaffold (brs) magmaris vs biodegradable polymer des ultimaster in nste-acs population-12-month clinical outcome. *Journal of interventional cardiology*. 2022;2022:5223317

heart disease, PCI = percutaneous coronary intervention. Data is shown as mean \pm standard

deviation.

561

Version 4.6 18.6.24

Scaffold measurement						
Total number of analyzable struts	199.9 ± 70.5	210.7 ± 60.0	0.46	70.8 ± 35.1	85.1 ± 32.1	0.07
Mean no. of struts per cross	9.11 ± 0.71	9.11 ± 0.82	1.00	3.1 ± 1.3	3.9 ± 1.7	0.03
section						
Scaffold length, mm	20.8 [16.5 ; 24.1]	22.2 [19.2; 24.8]	0.51	20.4 [17.2; 24.0]	$\overline{21.0}$ [17.2; 25.2]	0.69
Minimal scaffold area, mm ²	6.40 ± 1.50	6.09 ± 1.51	0.36			
Mean scaffold area, mm ²	7.77 ± 1.49	7.45 ± 1.69	0.37			
Total scaffold volume, mm ³	161.81 ± 45.93	160.88 ± 52.44	0.93			
Scaffold malapposition						
Scaffold malapposition, n (%)	20(50.0)	21(55.3)	0.64	6(15.4)	15(42.9)	0.009
Total malapposition volume, mm ³	0.38 [0.15; 0.95]	1.07 [0.48; 2.27]	0.09	$\overline{0.0}$ [0.0; 0.0]	0.21 [0.0; 0.59]	0.009
Mean malapposition distance, mm	0.23 [0.21; 0.28]	0.30 [0.25; 0.34]	0.003	0.0 [0.0; 0.0]	0.18 [0.0; 0.4]	0.004
Percentage of malapposed struts, $\%$	1.5 [0.6; 3.0]	4.57 [1.7; 5.8]	0.02	0.0 [0.0; 0.0]	1.6 [0.0; 3.5]	0.004
Types of incomplete stent apposition						
Resolved, n (%)				17(48.6)	11(31.4)	0.28
Persistent, n (%)				2(5.0)	7(20.0)	0.05
Late acquired, $n(\frac{96}{2})$				4(10.3)	8(22.9)	0.14

Version 4.6 18.6.24

563

Table 4: Remodeling of lesion segment pre-procedure and corresponding segment post-

procedure and at 6-month follow-up assessed with IVUS

Version 4.6 18.6.24

Figures and legends

Figure 1: Flow chart

Figure 2: Intravascular images of lumen reduction after implantation of Magmaris bioresorbable scaffold.

 The upper panel shows OCT images of minimal lumen area from baseline and the corresponding site at follow-up. The lower panel shows the matching site acquired with IVUS. Images A and B represent the vascular healing after lesion preparation with a scoring balloon prior 572 to MgBRS implantation. Lumen area at baseline was 7.3 mm² measured with OCT and 7.5 mm² with IVUS. Vessel area was 12.7 mm² at

Version 4.6 18.6.24

- 573 baseline (A). At 6-month follow-up, lumen area was 8.8 mm² with OCT and 8.8 mm² with IVUS. Vessel area was 16.0 mm² (B). Images C
- 574 and D represent the vascular healing after implantation of a MgBRS in a lesion pre-dilated with a standard non-compliant balloon. Lumen
- 575 area at baseline was 8.8 mm² with OCT and 8.8 mm² with IVUS. Vessel area was 16.0 mm² (C). After 6 months, the matching site was
- 576 reduced to 5.1 mm² measured with OCT, and 5.6 mm² with IVUS. Vessel area was 13.8 mm² (D). Abbreviations: IVUS = Intravascular
- 577 ultrasound; MgBRS = Magmaris bioresorbable scaffold; OCT = Optical coherence tomography.

Figure 3: Optical coherence tomography images of malapposition types

 Upper panel represents baseline optical coherence tomography images, and lower panel represents 6-month follow-up. A) There are three malapposed struts from 3 to 5 o'clock, and one malapposed strut at 10 o'clock. The corresponding site after 6 months (B) revealed resolved malapposition from 3 to 5 o'clock, but persistent malapposition at 10 o'clock. C) Four malapposed struts are visible at baseline from 5 to 7 o'clock. At 6-month follow-up, persistent malapposition is seen in the corresponding cross section (D). E) All struts are well-apposed, but after 6 month acquired malapposition appears at 7 to 8 o'clock.

Version 4.6 18.6.24

Figure 4: Pattern of remodeling at the lesion site

A. Correlation between relative change in lumen area (%) and relative change in vessel area (%) at the lesion site. B. Correlation between relative change in lumen area (%) and relative change in plaque area at the lesion site

